211 related articles for article (PubMed ID: 24081029)
1. Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression.
Hart MR; Su HY; Broka D; Goverdhan A; Schroeder JA
Mol Ther; 2013 Nov; 21(11):1996-2007. PubMed ID: 24081029
[TBL] [Abstract][Full Text] [Related]
2. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.
Maisel SA; Broka D; Atwell B; Bunch T; Kupp R; Singh SK; Mehta S; Schroeder J
J Transl Med; 2019 Jun; 17(1):201. PubMed ID: 31215437
[TBL] [Abstract][Full Text] [Related]
3. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
4. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
Khan IH; Zhao J; Ghosh P; Ziman M; Sweeney C; Kung HJ; Luciw PA
Assay Drug Dev Technol; 2010 Feb; 8(1):27-36. PubMed ID: 20035613
[TBL] [Abstract][Full Text] [Related]
5. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
Anderson NG; Ahmad T
Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
[TBL] [Abstract][Full Text] [Related]
6. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
[TBL] [Abstract][Full Text] [Related]
7. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
[TBL] [Abstract][Full Text] [Related]
8. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
9. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
10. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
11. A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration in vitro and xenograft tumor growth in vivo.
Xu R; Povlsen GK; Soroka V; Bock E; Berezin V
Cell Oncol; 2010 Jan; 32(4):259-74. PubMed ID: 20364069
[TBL] [Abstract][Full Text] [Related]
12. Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.
Kleiman LB; Maiwald T; Conzelmann H; Lauffenburger DA; Sorger PK
Mol Cell; 2011 Sep; 43(5):723-37. PubMed ID: 21884975
[TBL] [Abstract][Full Text] [Related]
13. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
14. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Kedrin D; Wyckoff J; Boimel PJ; Coniglio SJ; Hynes NE; Arteaga CL; Segall JE
Clin Cancer Res; 2009 Jun; 15(11):3733-9. PubMed ID: 19458057
[TBL] [Abstract][Full Text] [Related]
15. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
16. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
17. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Stern DF
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
20. Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling.
Menezes SV; Sahni S; Kovacevic Z; Richardson DR
J Biol Chem; 2017 Aug; 292(31):12772-12782. PubMed ID: 28615452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
